Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
 

Corporate Investor Presentation

Rigel Corporate Investor Presentation

More »
Recent News
DateTitle 
08/06/19
TAVALISSE® net product sales increased 26% quarter over quarter to $10.2 million First patients enrolled in Phase 3 pivotal trial of TAVALISSE in warm autoimmune hemolytic anemia (AIHA) Conference call and webcast today at 4:30PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug.
07/30/19
SOUTH SAN FRANCISCO , July 30, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2019 financial results after market close on Tuesday, August 6 , 2019.  Rigel senior management will follow the announcement with a live conference
06/13/19
SOUTH SAN FRANCISCO , June 13, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters at the 24 th Congress of the European Hematology Association (EHA) in Amsterdam, The

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)
Volume
Data as of
More »
Upcoming Events
More events are coming soon.
What's New

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site